{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-000123","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.545048+00:00","generated_at":"2026-06-20T18:04:44.277614+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Passage Bio reports ~$190M cash as of Dec 31, 2022; runway into H1 2025","bullets":["Preliminary unaudited cash, equivalents and marketable securities of ~$190M at Dec 31, 2022.","Cash runway expected to fund operating expenses and capex into first half of 2025.","Update provided in January 9, 2023 corporate presentation; figures subject to audit.","No other financial results or guidance changes disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-000123","json":"https://secwatch.observer/filing/0001558370-23-000123.json","markdown":"https://secwatch.observer/filing/0001558370-23-000123.md","text":"https://secwatch.observer/filing/0001558370-23-000123.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023000123/0001558370-23-000123-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023000123/pasg-20230109x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:04:44.277614+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}